DANA-FARBER CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
NeoVax With Nivolumab in Patients With Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT04024878
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
INTREPId (INTermediate Risk Erection PreservatIon Trial)
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 234
- Registration Number
- NCT04025372
- Locations
- 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women Hospital, Boston, Massachusetts, United States
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Conditions
- Juvenile Myelomonocytic LeukemiaMyelodysplastic SyndromesAcute Myeloid LeukemiaMyeloproliferative Neoplasm
- Interventions
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT04024761
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
- Conditions
- Melanoma Stage IIIMelanoma Stage IV
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT04007588
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT03999684
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids
- Conditions
- Gynecologic Tumor
- Interventions
- Device: Magnetic Resonance Fingerprinting (MRF)Device: Q-space Trajectory Imaging (QTI)Device: Magnetic Resonance Imaging Machine (MRI)
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT03993210
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Talazoparib for Cohesin-Mutated AML and MDS with Excess Blasts
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT03974217
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer
- Conditions
- Cervical CancerGynecologic Cancer
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT03970083
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
- Conditions
- Brain Tumor, PediatricSolid Tumor, ChildhoodLymphoma
- Interventions
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 41
- Registration Number
- NCT03936465
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
- Conditions
- Cutaneous Melanoma
- Interventions
- First Posted Date
- 2019-04-26
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT03929029
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States